Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report Download FREE Resources

Published: July 09, 2026 Report Code: GDHC031MV-ST

Select Item

Analyze the global Focal Segmental Glomerulosclerosis therapeutics market, covering disease epidemiology, marketed and pipeline therapies, clinical trials, pricing, reimbursement, deals, and competitive dynamics.

Why Does the FSGS Therapeutics Market Matter?

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease characterized by scarring of the glomeruli and can lead to progressive kidney dysfunction. The treatment landscape is undergoing a significant shift as disease-specific therapies emerge alongside established supportive and off-label treatment approaches.

GlobalData’s Focal Segmental Glomerulosclerosis (FSGS): Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with in-house analyst expertise.

In 2025, there were 37,049 incident cases of FSGS across the 16 countries covered in GlobalData’s epidemiology forecast. The competitive landscape is also evolving, with Filspari (sparsentan) receiving FDA approval for FSGS in April 2026, marking the first FDA-approved therapy specifically indicated for the condition.

The report provides detailed insight into:

  • FSGS epidemiology and disease burden
  • Current treatment approaches and marketed products
  • Emerging pipeline therapies
  • Clinical trial activity
  • Pricing and reimbursement
  • Annual therapy costs
  • Deals, acquisitions, and strategic alliances
  • Key market players and future market catalysts

Key Insights in the FSGS Therapeutics Market

The report highlights a rapidly evolving treatment landscape following the emergence of disease-specific therapy.

Key themes include:

  • 37,049 incident FSGS cases across 16 countries in 2025
  • The 2021 KDIGO guideline for FSGS diagnosis and treatment across the seven major markets
  • The emergence of on-label disease-specific treatment after years of reliance on supportive and off-label approaches
  • Filspari (sparsentan) becoming the first FDA-approved therapy specifically indicated for FSGS in April 2026
  • A pipeline containing 45 molecules
  • Five pipeline assets in Phase III development
  • 13 pipeline assets in Phase II development
  • 90 FSGS clinical trials conducted over the past decade
  • Increasing deal activity across North America, Europe, and Asia-Pacific

Scope

What Will You Learn from This FSGS Therapeutics Market Report?

This report provides insight into:

  • FSGS disease landscape and overview

  • Epidemiology and incident cases

  • Current treatment approaches

  • Marketed product performance

  • Mechanism of action and molecule type analysis

  • Product profiles and sales forecasts

  • Pricing and reimbursement

  • Annual therapy costs

  • Time to pricing and reimbursement

  • Pipeline products by development stage

  • Pipeline products by mechanism of action

  • Pipeline products by molecule type

  • Pipeline products by route of administration

  • Clinical trial activity and trends

  • Phase transition success rates

  • Likelihood of approval

  • Deals, acquisitions, and strategic alliances

  • Key market players

  • Future market catalysts

Target Buyers for This FSGS Therapeutics Market Report

This report may be valuable for:

  • Pharmaceutical companies

  • Biotechnology companies

  • Drug developers

  • Commercial strategy teams

  • Clinical development teams

  • Market access professionals

  • Business development and licensing teams

  • Healthcare investors

  • Private equity firms

  • Healthcare consultants and advisors

  • Market intelligence professionals

How Companies Use This FSGS Market Analysis

Pharmaceutical and biotechnology companies can use the report to assess the evolving competitive landscape and identify opportunities for product development, licensing, and strategic partnerships.

Business development teams can evaluate pipeline assets, deal activity, and companies with potentially strong portfolios to support in-licensing and out-licensing strategies.

Commercial teams can use sales forecasts, competitive analysis, and market catalysts to develop sales and marketing strategies.

Investors can assess pipeline maturity, clinical development activity, market access factors, and competitive positioning to identify potential investment opportunities.

Reasons to Buy

Benchmark the FSGS Therapeutics Market Against Key Players

The report helps pharmaceutical companies and investors benchmark the FSGS market through analysis of:

  • Marketed products

  • Pipeline assets

  • Product sales forecasts

  • Mechanisms of action

  • Molecule types

  • Clinical development activity

  • Pricing and reimbursement

  • Deal activity

  • Competitive positioning

By combining these metrics, stakeholders can identify emerging competitors and assess the potential impact of new therapies on the future market.

Develop Strategic Opportunities in the FSGS Therapeutics Market

The report supports strategic decision-making across the FSGS treatment landscape.

Stakeholders can use the analysis to:

  • Develop in-licensing and out-licensing strategies

  • Identify companies with strong FSGS pipelines

  • Assess emerging therapies and technologies

  • Understand clinical development trends

  • Evaluate competitive positioning

  • Identify potential market gaps

  • Assess pricing and reimbursement dynamics

  • Monitor mergers, acquisitions, and strategic alliances

  • Identify opportunities for consolidation and investment

  • Develop competitive counter-strategies

Built on GlobalData Pharma Intelligence

GlobalData’s FSGS Market View combines data from the Pharma Intelligence Center with analyst expertise to provide a comprehensive assessment of the disease landscape.

The report brings together epidemiology, treatment, marketed products, pipeline therapies, clinical trials, pricing and reimbursement, deals, and competitive analysis to help stakeholders understand the current market and anticipate the future direction of FSGS therapeutics.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Product Profile and Sales Forecast

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

7.1 Pipeline Drugs

7.2 Overview by Development Stage

7.3 Overview by Mechanism of Action

7.4 Overview by Molecule Type

7.5 Overview by Route of Administration

7.6 Product Profile and Sales Forecast

7.7 Drug-specific PTSR and LoA

7.8 Therapy Area-specific PTSR and LoA

8 Clinical Trials Assessment

8.1 Historical Overview

8.2 Overview by Phase

8.3 Overview by Status

8.4 Overview by Phase for Ongoing and Planned Trials

8.5 Trials with Virtual Components

8.6 Top 20 Biomarkers by Trial Phase

8.7 Overview of Trials by Geography

8.8 Single-Country and Multinational Trials by Region

8.9 Top 20 Sponsors with Breakdown by Phase

8.10 Top 20 Sponsors with Breakdown by Status

8.11 Overview by Endpoint Status

8.12 Overview by Race and Ethnicity

8.13 Enrollment Data

8.14 Top 20 countries for Trial Sites

8.15 Top 20 Sites Globally

8.16 Feasibility Analysis – Geographic Overview

8.17 Feasibility Analysis – Benchmark Models

9 Deals Landscape

9.1 Mergers, Acquisitions, and Strategic Alliances by Region

9.2 Recent Mergers, Acquisitions, and Strategic Alliances

10 Commercial Assessment

10.1 Key Market Players

11 Future Market Catalysts

12 Appendix

12.1 Methodology

12.2 Methodology – Sales Forecast

12.3 Methodology – Pricing and Reimbursement

12.4 Methodology – PTSR and LoA Analysis

12.5 About the Authors

12.6 Contact Us

12.7 Disclaimer

Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Focal Segmental Glomerulosclerosis (FSGS) reports
Pharmaceuticals
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Pharmaceuticals
New
Pharmaceutical Drug Development Annual Review 2025
$1,200 | August 2026
Pharmaceuticals
New
Q2 2026 CRO Activity and Intel Report
$1,870 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape in real time.

  • Access a live Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more